Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
16.48
-0.74 (-4.30%)
At close: Nov 20, 2026, 4:00 PM EST
16.50
+0.02 (0.12%)
After-hours: Nov 20, 2026, 7:31 PM EST
Ultragenyx Pharmaceutical Revenue
Ultragenyx Pharmaceutical had revenue of $173.00M in the quarter ending September 30, 2026, with 8.13% growth. This brings the company's total for the last twelve months to $730.00M, up 15.75% year-over-year. In the year 2025, Ultragenyx Pharmaceutical had annual revenue of $673.00M with 20.18% growth. That makes Ultragenyx Pharmaceutical the 9,202nd largest company in the world by revenue and 2,040th in the United States.
Revenue (ttm)
$730.00M
Revenue Growth
+15.75%
P/S Ratio
2.29
Revenue / Employee
$532,458
Employees
1,371
Market Cap
1.67B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Ultragenyx Pharmaceutical breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 673.00M | 113.00M | 20.18% |
| Dec 31, 2024 | 560.00M | 126.00M | 29.03% |
| Dec 31, 2023 | 434.00M | 70.67M | 19.45% |
| Dec 31, 2022 | 363.33M | 11.92M | 3.39% |
| Dec 31, 2021 | 351.41M | 80.38M | 29.66% |
| Dec 31, 2020 | 271.03M | 167.32M | 161.32% |
| Dec 31, 2019 | 103.71M | 52.22M | 101.41% |
| Dec 31, 2018 | 51.50M | 48.88M | 1,871.48% |
| Dec 31, 2017 | 2.61M | 2.48M | 1,863.91% |
| Dec 31, 2016 | 133.00K | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.67B |
| Zymeworks | 265.97M |
| Maravai LifeSciences Holdings | 213.00M |
| Agios Pharmaceuticals | 140.84M |
| Stoke Therapeutics | 28.21M |
| Maze Therapeutics | 20.00M |
| Zenas BioPharma | 11.00M |
RARE News
- 5 days ago - Ultragenyx Pharmaceutical Transcript: Jefferies Global Healthcare Conference - Transcripts
- 5 days ago - Ultragenyx price target lowered to $24 from $35 at Guggenheim - TheFly
- 5 days ago - Ultragenyx Pharmaceutical Transcript: UBS Global Biopharma Conference 2026 - Transcripts
- 11 days ago - Ultragenyx to Participate at Investor Conferences in London - GlobeNewsWire
- 16 days ago - Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare Products Regulatory Agency (MHRA) - GlobeNewsWire
- 16 days ago - Ultragenyx price target lowered to $22 from $32 at Citi - TheFly
- 17 days ago - Ultragenyx price target lowered to $32 from $35 at Barclays - TheFly
- 18 days ago - Ultragenyx price target raised to $19 from $18 at TD Cowen - TheFly